CD20-targeted measles virus shows high oncolytic specificity in clinical samples from lymphoma patients independent of prior rituximab therapy

K. C. Yaiw, T. S. Miest, M. Frenzke, M. Timm, Patrick Bruce Johnston, Roberto Cattaneo

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

New therapeutic modalities for B-cell non-Hodgkin's lymphomas (B-NHL) are needed, especially for relapsing and aggressive subtypes. Toward this end, we previously generated a fully CD20-targeted and armed measles virus, and tested its efficacy in a xenograft model of mantle cell lymphoma (MCL). Here, we quantify its spread in peripheral blood mononuclear cells and/or tissue of patients with different histological subtypes of B-NHL, including splenic marginal zone lymphoma (SMZL). CD20-targeted MV efficiently infects lymphoma cells from SMZL and MCL while sparing most cells in the CD20-negative population, in contrast to the parental vaccine-lineage MV, which infects CD20-positive and CD20-negative cells equally. Rituximab therapy (4-8 months before relapse) did not interfere with the infectivity and specificity of MVgreenHblind antiCD20 in patient lymphoma samples. Thus, CD20-targeted oncolytic virotherapy is likely to be effective after previous antiCD20 therapy.

Original languageEnglish (US)
Pages (from-to)313-317
Number of pages5
JournalGene Therapy
Volume18
Issue number3
DOIs
StatePublished - Mar 2011

Fingerprint

Measles virus
Mantle-Cell Lymphoma
Lymphoma
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Oncolytic Virotherapy
Heterografts
Blood Cells
Therapeutics
Vaccines
Recurrence
Population
Rituximab

Keywords

  • CD-20
  • lymphoma
  • oncolytic virotherapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

CD20-targeted measles virus shows high oncolytic specificity in clinical samples from lymphoma patients independent of prior rituximab therapy. / Yaiw, K. C.; Miest, T. S.; Frenzke, M.; Timm, M.; Johnston, Patrick Bruce; Cattaneo, Roberto.

In: Gene Therapy, Vol. 18, No. 3, 03.2011, p. 313-317.

Research output: Contribution to journalArticle

@article{07cf270891cc44fd8652d8dbdf80e9b2,
title = "CD20-targeted measles virus shows high oncolytic specificity in clinical samples from lymphoma patients independent of prior rituximab therapy",
abstract = "New therapeutic modalities for B-cell non-Hodgkin's lymphomas (B-NHL) are needed, especially for relapsing and aggressive subtypes. Toward this end, we previously generated a fully CD20-targeted and armed measles virus, and tested its efficacy in a xenograft model of mantle cell lymphoma (MCL). Here, we quantify its spread in peripheral blood mononuclear cells and/or tissue of patients with different histological subtypes of B-NHL, including splenic marginal zone lymphoma (SMZL). CD20-targeted MV efficiently infects lymphoma cells from SMZL and MCL while sparing most cells in the CD20-negative population, in contrast to the parental vaccine-lineage MV, which infects CD20-positive and CD20-negative cells equally. Rituximab therapy (4-8 months before relapse) did not interfere with the infectivity and specificity of MVgreenHblind antiCD20 in patient lymphoma samples. Thus, CD20-targeted oncolytic virotherapy is likely to be effective after previous antiCD20 therapy.",
keywords = "CD-20, lymphoma, oncolytic virotherapy",
author = "Yaiw, {K. C.} and Miest, {T. S.} and M. Frenzke and M. Timm and Johnston, {Patrick Bruce} and Roberto Cattaneo",
year = "2011",
month = "3",
doi = "10.1038/gt.2010.150",
language = "English (US)",
volume = "18",
pages = "313--317",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - CD20-targeted measles virus shows high oncolytic specificity in clinical samples from lymphoma patients independent of prior rituximab therapy

AU - Yaiw, K. C.

AU - Miest, T. S.

AU - Frenzke, M.

AU - Timm, M.

AU - Johnston, Patrick Bruce

AU - Cattaneo, Roberto

PY - 2011/3

Y1 - 2011/3

N2 - New therapeutic modalities for B-cell non-Hodgkin's lymphomas (B-NHL) are needed, especially for relapsing and aggressive subtypes. Toward this end, we previously generated a fully CD20-targeted and armed measles virus, and tested its efficacy in a xenograft model of mantle cell lymphoma (MCL). Here, we quantify its spread in peripheral blood mononuclear cells and/or tissue of patients with different histological subtypes of B-NHL, including splenic marginal zone lymphoma (SMZL). CD20-targeted MV efficiently infects lymphoma cells from SMZL and MCL while sparing most cells in the CD20-negative population, in contrast to the parental vaccine-lineage MV, which infects CD20-positive and CD20-negative cells equally. Rituximab therapy (4-8 months before relapse) did not interfere with the infectivity and specificity of MVgreenHblind antiCD20 in patient lymphoma samples. Thus, CD20-targeted oncolytic virotherapy is likely to be effective after previous antiCD20 therapy.

AB - New therapeutic modalities for B-cell non-Hodgkin's lymphomas (B-NHL) are needed, especially for relapsing and aggressive subtypes. Toward this end, we previously generated a fully CD20-targeted and armed measles virus, and tested its efficacy in a xenograft model of mantle cell lymphoma (MCL). Here, we quantify its spread in peripheral blood mononuclear cells and/or tissue of patients with different histological subtypes of B-NHL, including splenic marginal zone lymphoma (SMZL). CD20-targeted MV efficiently infects lymphoma cells from SMZL and MCL while sparing most cells in the CD20-negative population, in contrast to the parental vaccine-lineage MV, which infects CD20-positive and CD20-negative cells equally. Rituximab therapy (4-8 months before relapse) did not interfere with the infectivity and specificity of MVgreenHblind antiCD20 in patient lymphoma samples. Thus, CD20-targeted oncolytic virotherapy is likely to be effective after previous antiCD20 therapy.

KW - CD-20

KW - lymphoma

KW - oncolytic virotherapy

UR - http://www.scopus.com/inward/record.url?scp=79952486788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952486788&partnerID=8YFLogxK

U2 - 10.1038/gt.2010.150

DO - 10.1038/gt.2010.150

M3 - Article

VL - 18

SP - 313

EP - 317

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 3

ER -